[68Ga]Ga-PSMA-11 PET/CT for staging and patient management of high-risk prostate cancer: A single-center experience from Iran
Authors
Abstract:
Introduction: Accurate staging plays an important role in management of patients with prostate cancer especially in high-risk group. Today, [68Ga]Ga-PSMA-11 PET/CT should be considered as the preferred imaging tool for treatment planning and initial staging of the disease. Methods: A total number of 628 patients with prostate cancer referred to Razavi hospital nuclear medicine department between March 2016 and December 2019. Among 103 patients in initial staging category, 23 cases met our inclusion criteria and entered the study. All patients performed CT scan or MRI accompanied with bone scintigraphy before [68Ga]Ga-PSMA-11 PET/CT. The scan results were compared with conventional imaging and their treatment plan determined before and after performing[68Ga]Ga-PSMA-11 PET/CT. Results: The detection rate of [68Ga]Ga-PSMA-11 PET/CT was superior to CT/MRI in local lymph node involvements (56.5% to 21.7%), as well as for distant metastases (47.83% to 13%). The scan findings lead to upstaging in 9 patients and down staging in 4 patients.[68Ga]Ga-PSMA-11 PET/CT results changes the therapeutic plan in 13 patients (56.5%). Conclusion: [68Ga]Ga-PSMA-11 PET/CTis a promising imaging tool for initial staging of high-risk prostate cancer patients with significant higher detection rate in comparison to the conventional imaging. The study showed 56.5% changes in treatment planning following [68Ga]Ga-PSMA-11 PET/CT study.
similar resources
68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
We evaluated the clinical utility of 68Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic le...
full textManual production and quality control of 68Ga-PSMA-11 radiopharmaceutical for PET-CT imaging of prostate cancer: optimization and 60 production series experience
Background: 68Ga-PSMA-11, a novel PET radiopharmaceutical, is currently used for imaging of almost all prostate cancers. However, automatic radiolabeling procedures have been recommended. In this research, according to the chemical nature of the PSMA-11, manual, optimized and safe production of this radiopharmaceutical has been investigated and a standard method has been presented to achieve a ...
full textI-124 pre-therapy dosimetry for the treatment of differentiated thyroid cancer: A single center experience
Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...
full textHealthcare Resource Management and Pandemic Preparedness for COVID-19: A Single Centre Experience From Jodhpur, India
full text
Bone scintigraphy in staging of newly diagnosed prostate cancer in regard of different risk groups
Objective(s): Prostate cancer (PC) is the most common cancer in men over 50 years of age. Bone scintigraphy is still performed in many institutions at the time of primary diagnosis. We aimed to evaluate the role of bone scan in the primary staging of PC in regard of different risk groups. Methods: A retrospective analysis of bone scans i...
full textMy Resources
Journal title
volume 30 issue 1
pages 33- 39
publication date 2022-01-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023